Suzhou Yuanju Medical Technology Co Ltd, a company in SIP, and Hunan Jiudian Pharmaceutical Co Ltd, a pharmaceutical company headquartered in Changsha, Central China’s Hunan province, signed a patent and technology transfer agreement in Changsha on Dec 15 for the industrialization of the small-molecule analgesic drug YJ2301 developed by a team led by Prof. Li Fei at the School of Pharmacy of Nanjing Medical University. The total transaction value approaches RMB400 million.

TheYJ2301 is an innovative analgesic that employs a novel mechanism to address common side effects such as drowsiness and drug tolerance associated with existing painkillers. It has gone through part of the preclinical studies, with related patent applications submitted.

Under the agreement, Jiudian Pharmaceutical obtains the global ownership and intellectual property rights of YJ2301. This will enrich its product pipeline and also strengthen its competitiveness in the analgesic market.

The Regional University-Industry Technology Transfer Center for Biopharmaceuticals (Suzhou, Jiangsu) has provided comprehensive support for the YJ2301 project, including proof of concept and commercialization planning and will offer follow-up assistance to it.

December 16, 2025